Press Releases

FORNEBU, Norway, June 3, 2024 /PRNewswire/ -- Akastor ASA's (OSE: AKAST) 50% owned affiliate HMH Holding B.V. ("HMH") has today announced that its subsidiary HMH Holding Inc. has submitted a confidential first draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of HMH Holding Inc.'s shares. This filing represents the first step of a possible US listing of HMH.

The size and... (continue reading...)

BW Energy: Appraisal confirms material Hibiscus field reserve increase

Reference is made to the stock exchange notice by BW Energy on 20 May 2024 announcing a substantial oil discovery on the northern flank of the Hibiscus field.

BW Energy has now concluded the drilling and the logging of the DHIBM-7P pilot well, confirming a substantial oil discovery with good reservoir quality and a material uplift to the Hibiscus area.

The Company’s preliminary evaluation... (continue reading...)

GENEVA, SWITZERLAND / ACCESSWIRE / June 3, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company. Her contract was not renewed upon its expiration on May 31, 2024.

• CHMP opinion paves the way for Marketing Authorisation approval by the European Commission, currently anticipated in early August 2024.
• When approved, AKANTIOR will be the first licensed medicinal product for the treatment of acanthamoeba keratitis, a rare, severe eye infection that often results in blindness and eye loss.
• Phase III ODAK study demonstrated 87% of patients receiving AKANTIOR were cured within a median time of 4 months.
• AKANTIOR will be... (continue reading...)

Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (Cosmo) with its Cosmo Intelligent Medical Devices division (Cosmo IMD) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes.

GI Genius" has been conceived and is being designed, developed,... (continue reading...)